



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Suvizumab

Cat. No.:	HY-P99584
CAS No.:	914257-21-9
Target:	HIV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1 _{MN} , HIV-1 _{SF2} and HIV-1 _{89.6} with IC ₅₀ values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection ^{[1][2]} .			
IC₅₀ & Target	HIV-1	HIV-1 _{89.6} 0.2 µg/mL (IC ₅₀)	HIV-1 _{MN} 0.1 µg/mL (IC ₅₀)	HIV-1 _{SF2} 1.0 µg/mL (IC ₅₀)
In Vitro	Suvizumab shows highly resistant to pseudotyped virus with the G314E mutation ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	Suvizumab (15, 30 and 45 mg/kg; i.v.; single dose) attenuates viral attack and plasma viremia, and increased the number of CD4 ⁺ T cells in SHIV C2/1 infected cynomolgus monkeys with dose-dependent manner ^[2] . Suvizumab (45 mg/kg; i.v.; once a week for 2 months) reduces the loss of CD4 T cells in lymphoid tissue in male cynomolgus monkeys infected with simian/human immunodeficiency virus-C2/1 ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

- [1]. Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. *AIDS*. 2015 Feb 20;29(4):453-62.
- [2]. Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. *J Virol*. 2006 Jun;80(11):5563-70.
- [3]. Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. *AIDS*. 2006 Oct 24;20(16):2065-73.
- [4]. Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4⁺ T-cell loss in macaque lymphoid tissue. *AIDS*. 2009 Jul 31;23(12):1485-94.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA